Largest CRISPR Companies by Market Cap (April 2025)

As of April 16, 2025, we have calculated the total market capitalization of 4 publicly traded CRISPR companies, amounting to $5.68 billion.

$5.68 B

CRISPR Market Cap -3.93%

$948276.0

24h Trading Volume

According to our market capitalization data, CRISPR Therapeutics (CRSP) reached a market cap of $3.22 billion, securing the top spot among global CRISPR companies. Beam Therapeutics (BEAM) and Intellia Therapeutics (NTLA) follow closely behind. The data was last updated on April 16, 2025.

Rank	Name	Market Cap	Price	MCap(30D)	MCap(1Y)	Country
1	CRISPR Therapeutics CRSP	$3.22 B	$37.51	0.00%	-10.5%	Switzerland
2	Beam Therapeutics BEAM	$1.63 B	$16.32	0.00%	9.3%	United States
3	Intellia Therapeutics NTLA	$0.73 B	$7.01	0.00%	-55.4%	United States
4	Editas Medicine EDIT	$0.11 B	$1.29	0.00%	-78.6%	United States

This list ranks the largest CRISPR companies in the world by market capitalization, based on data from publicly traded CRISPR companies. The market cap figures and rankings on this list are updated daily.

What is Market Capitalization?

Market capitalization, or market cap, is a key measure of a company's market value. It is calculated by multiplying the current stock price by the total number of outstanding shares. Market cap is often used by investors to assess a company's size, stability, and market presence. For any inquiries or to report an issue, please email us at [email protected].

Disclaimer

This website provides general information only. While we aim for accuracy, we do not guarantee data completeness or reliability. Consult a financial advisor before investing. We are not responsible for any losses or damages from using this site. By using it, you agree to these terms. Company logos belong to their respective copyright holders and are shown for editorial purposes only. Prices are not in real time.

America

Europe

Asia

Others

Largest CRISPR Companies by Market Cap (April 2025)